| Budget Amount *help |
¥26,650,000 (Direct Cost: ¥20,500,000、Indirect Cost: ¥6,150,000)
Fiscal Year 2013: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2012: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2011: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2010: ¥11,180,000 (Direct Cost: ¥8,600,000、Indirect Cost: ¥2,580,000)
|
|---|
| Research Abstract |
The minimal residual disease assay by the gene analysis in canine lymphoid neoplasms was established and showed extremely useful for curative effect and a prognostic evaluation. In addition, plural tumor-related factors abnormality was clarified, and a part participated in the outcome and indicated to be with candidate novel treatment target molecules. Furthermore, the cytomorphological classification in feline lymphomas was established and it was clarified that the malignancy according to the classification was significantly associated with the outcome. On the other hand, antitumor effects of molecular target agents were analyzed in canine mastocytoma and the results showed potentials of novel treatment strategy. Furthermore, genetic mutations and the malignancy classification of canine mastocytoma participated in treatment efficacy and the outcome. The results are extremely useful for treatment guidelines and the prognostic evaluation in hematological neoplasms of animals.
|
